Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine.
about
Further evidence for favorable cost-effectiveness of elderly influenza vaccinationInfluenza vaccination coverage among school employees: assessing knowledge, attitudes, and behaviorsVaccines for preventing influenza in healthy adultsVaccines for preventing influenza in healthy adultsVaccines for preventing influenza in healthy adultsMeasuring Cellular Immunity to Influenza: Methods of Detection, Applications and ChallengesThe Saudi Thoracic Society guidelines for influenza vaccinationsProbabilistic sensitivity analysis in health economics.Clinical and socioeconomic impact of seasonal and pandemic influenza in adults and the elderly.Trivalent intranasal influenza vaccine, live.The costs of preventing the spread of respiratory infection in family physician offices: a threshold analysis.Influence of prior influenza vaccination on antibody and B-cell responses.Effectiveness of alcohol-based hand disinfectants in a public administration: impact on health and work performance related to acute respiratory symptoms and diarrhoeaViral lower respiratory tract infection in infants and young children.Workplace vaccination and other factors impacting influenza vaccination decision among employees in Israel.Seasonal influenza vaccination of healthy working-age adults: a review of economic evaluations.From the patient perspective: the economic value of seasonal and H1N1 influenza vaccination.Cost-benefit analysis of influenza vaccination in a public healthcare unit.Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines.Cold-adapted, live attenuated influenza vaccine.Control of influenza.A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individualsLocal and systemic cytokine and chemokine responses after parenteral influenza vaccination.Immunogenicity of a reduced dose of A/H3N2 in the 2005 southern hemisphere formulation of inactivated split influenza vaccine.The Impact of Patient's Socio-Demographic Characterictics, Comorbidities and Attitudes on Flu Vaccination Uptake in Family Practice Settings.Prevention and control of influenza in persons with chronic obstructive pulmonary diseaseInfluenza-like illness among university students: symptom severity and duration due to influenza virus infection compared to other etiologiesVaccinations administered during off-clinic hours at a national community pharmacy: implications for increasing patient access and convenience.Racial and ethnic disparities in influenza vaccinations among community pharmacy patients and non-community pharmacy respondents.Influenza vaccines in low and middle income countries: a systematic review of economic evaluations.Improving immunization rates: initial results from a team-based, systems change approach.Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.Prisons show prophylaxis for close contacts may indeed help in next flu pandemic.The burden of influenza-like illness in the US workforce.
P2860
Q22305948-2C416E1A-A494-42F3-871A-6BADC9281066Q23917653-9BB48C74-52AC-4C6F-8B8E-FC347792DE19Q24197955-6263CBA5-83E0-400A-8B09-2400EFCA93C5Q24234114-C9267E5D-B138-470C-B35B-641446ABA63FQ24245429-8E8AC19C-5048-482C-89AF-D71E6485CC2EQ26783884-1D1371E3-19EC-4B2B-84E1-CEF39DCD2323Q28394218-9359D91F-B7FB-4052-8EC3-0A46B11477EBQ30407247-DA72AD54-B97E-4881-A79C-9B849C8B52FCQ30411874-1C216501-EEB3-4DF8-B0EA-867428F1B057Q30434868-A64B2901-84E0-4209-A0D1-1787E1618124Q30838592-E44E6186-2D5E-4554-8D24-18DE4840B9E5Q33361605-FABF7A99-D153-49B4-B2B3-DF7CE6DDDAD6Q33671482-45EA9180-41DD-4041-8420-9A8DE95FFDCCQ33815604-D1607E09-A78F-40E0-B506-DD133812047DQ33858866-62B6C80B-08BB-4853-A0CE-128CA17222B6Q34242338-3345B789-8033-4F9F-95C0-A229E156CBD6Q34613417-BFA466D2-C828-410F-B7C6-74A244650C1FQ35166826-BD94429C-3D20-4FDB-A79B-1B05139C1752Q35634295-255B2328-9483-412C-838B-A735A1457902Q35728567-C2F858A9-F0FD-4144-BB9E-B44D1964101FQ35733952-2D41577A-AEF9-45A7-869B-29DE7F7089ADQ35815281-B85910BB-7B09-41FB-81D5-C8BB7126A898Q36252434-DE355387-319F-4B5E-8F7B-AE1375363ED4Q36252900-1B9F7942-CFF6-41A4-BC38-14374D133C31Q36763433-935A85DC-A6B1-4410-B436-0C83C283EAFFQ37017252-5B451E93-A4FB-4A19-83AC-1B1487136C62Q37094771-D9B59873-FE90-463C-B640-4B56AFE1CF9EQ37157659-8DD289E7-C743-403C-8E74-D189589B670AQ37381716-3276D86C-3C66-44A7-9D82-4A3CFC8A077BQ37472579-8636A561-08AC-4001-9B44-ED675E38DEABQ39102769-EB86BB05-4A3A-4354-9C82-30F439442A69Q39671799-966C23AE-8BA1-42D2-B746-C42718CEE15AQ42410174-188CD7CC-E803-43E0-9DCE-886B668629E2Q50132581-35403641-9A5B-4BD1-B70C-236CFF280C49
P2860
Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Cost benefit of influenza vacc ...... uated influenza virus vaccine.
@en
type
label
Cost benefit of influenza vacc ...... uated influenza virus vaccine.
@en
prefLabel
Cost benefit of influenza vacc ...... uated influenza virus vaccine.
@en
P2093
P1433
P1476
Cost benefit of influenza vacc ...... uated influenza virus vaccine.
@en
P2093
Kenneth P Mallon
Kristin L Nichol
Paul M Mendelman
P304
P356
10.1016/S0264-410X(03)00029-X
P407
P577
2003-05-01T00:00:00Z